BTK and B-cell chronic lymphocytic leukemia: BTK inhibitors (e.g. ibrutinib) have been developed to treat chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) by blocking BCR signaling and regulating innate/adaptive immunity [240].